Mabwell 9MW3011 injection was approved for clinical trials

On January 3, Mabwell announced that the clinical trial application of its self-developed 9MW3011 injection was officially approved by the National Medical Products Administration (NMPA), and clinical trials were carried out for iron overload-related indications and polycythemia vera in patients with β-thalassemia. At present, there are no mature and effective macromolecular therapeutics in the relevant indications, so 9MW3011 is expected to obtain orphan drug status in the future and become the first macromolecular drug in the world to regulate iron homeostasis in the body.

9MW3011 is an innovative target monoclonal antibody independently developed by Mabwell's San Diego Innovation R&D Center in the United States, which is a class 1 therapeutic biological product. The target of 9MW3011 is mainly expressed on the surface of hepatocyte membranes, which upregulates the level of hepcidin expression in hepatocytes by specifically binding to the target, inhibits the absorption and release of iron, and reduces serum iron levels, thereby regulating iron homeostasis in vivo.